[A16-15] Ticagrelor (new therapeutic indication) - Benefit assessment according to §35a Social Code Book V
Last updated 15.09.2016
Project no.:
A16-15
Commission:
Commission awarded on 21.03.2016 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Heart and circulation
Note:
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A16-52 | Ticagrelor (prevention of atherothrombotic events after myocardial infarction) – Addendum to Commission A16-15 | Commission completed |
| A11-02 | Ticagrelor - Benefit assessment according to § 35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-09-15 A G-BA decision was published.